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Current therapies for acute myeloid leukemia (AML), are associated
with high relapse rates. Hence, development of new therapeutic
strategies is crucial to circumvent this problem. Bivalent antibody
technology has been used to engineer novel antibody fragments
with increased avidity, by assembling two scFv in a single mole-
cule. Here, we present accompanying data from construction and
characterization experiments of a biscFv antibody targeting CD123,
the most important biomarker of leukemic cancer stem cells which
play a key role in relapsed AML after chemotherapy. Data in this
article are related to the research paper “Development of a novel
engineered antibody targeting human CD123” Moradi-Kalbolandi
S. et al. (2016) [1].
& 2016 Published by Elsevier Inc. This is an open access article
under the CC BY license
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ore speciﬁc sub-
ject areaAntibody Engineeringype of data Table, ﬁgure
ow data was
acquiredPCR, Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
Westernblotting, ELISA, Flow cytometryata format Raw, analyzed
xperimental
factorsAssembly and characterization of the anti-CD123 biscFv construct in pET22-b
expression vector and Periplasmic protein expression, puriﬁcation and char-
acterization of biscFvxperimental
featuresMolecular Biology methodologies(PCR, enzyme restriction, DNA ligation, Protein
expression), ﬂow cytometry, ELISAata source
locationTehran, Iranata accessibility Data is within this articleDValue of the data
 A detailed process for construction of an anti CD123 biscFv through scFv dimerization is described.
 The data include an experimental guide for construction of ﬂexible linker (G4S)3 by annealing of
2 overlapping oligonucleotides without any digestion needed for cloning purpose.
 Protein expression and puriﬁcation data show the expression and proper protein purity of con-
structed biscFv by Immobilized Metal Afﬁnity chromatography (IMAC).
 The methods and data describe the improvement of the biscFv functions over its parental scFv.1. Data
The cloning strategy for subsequent expression and puriﬁcation of anti-CD123 biscFv were
described (Figs. 1, 2 and Table 1). Expression data by SDS-PAGE and westernblotting were generated
to validate the construction of anti-CD123 biscFv plasmid (Fig. 3). The bivalent scFv exhibited
improved functionality compared to monovalent scFv antibody (Figs. 4A, 5 and Table 2).2. Experimental design, materials and methods
2.1. DNA constructs
The anti-CD123- scFv plasmid, encoding the murine anti-CD123 scFv was previously isolated from
our constructed scFv phage display library [2]. It is in the VH-linker-VL format, where the linker
consists of 18 amino acid residue of pSEX81 phagemid (PROGEN Biotechnik GmbH, Heidelberg,
Germany) (Fig. 1). Thus, scFv-110, was employed as PCR template for generation of biscFv-110, using
the primers shown in Table 1. DNA ampliﬁcation by PCR, digestion with restriction enzymes, ligation
and other standard cloning procedures are followed well established protocols [3]. Our biscFv, was
constructed by covalent linking of two individual scFv DNA sequences in tandem via a linker as shown
schematically in Fig. 1. This was achieved by ligation of PCR ampliﬁed scFv1, scFv2 fragments and
hybridized L fragment ((Gly4Ser)3 linker), as the building blocks, in to the pET22-b vector, separately
(Fig. 2). All the above PCR fragments were ampliﬁed with pfu high ﬁdelity DNA polymerase (Thermo
ﬁsher scientiﬁc, USA).
Fig. 1. Schematic generation of biscFv. A) dsDNA coding sequence for (Gly4Ser)3 linker results from annealing of synthesized
overlapping oligonucleotides L-1 and L-2, after heating for 10 min at 94 °C and cooling slowly to room temperature. Overhangs
of BamHI and EcoRI were formed after annealing for cloning purpose without digestion requirement. B) scFv-1, by PCR using
primer scFv1-F, scFv2-R with NcoI, BamHI restriction sites applied. C) scFv-2, by PCR using primer scFv2-F, scFv2-R with EcoRI,
NotI restriction sites applied. D) BiscFv cassette, results from cloning of scFv-1, linker, scFv-2 in to pET22-b vector respectively.
E) Protein form of biscFv.
Fig. 2. Construction of biscFv, colony PCR following insertion of each steps. A) Colony PCR following insertion of linker within
the plasmid. Lane M: GenRuler DNA ladder (Thermo ﬁsher scientiﬁc, USA), Lane V, the empty plasmid, Lane VþL 450 bp-
band, conﬁrmed the insertion of 50 bp linker (L) in to vector (V). B) Colony PCR after second cloning procedure. The 1250 bp-
band indicates the insertion of scFv1 in to the vector contains the linker (VþLþ scFv-1). C) Colony PCR of last step cloning. The
2000 bp-band indicates of biscFv (scFv1þLþscFv2).
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Table 1
Primers used for PCR of scFv genes and oligonucleotide for linker in order to biscFv
construction.
Oligonucleotide 5
0
to 3
0
sequencea
L1 GATCCGGTGGAGGCGGTTCAGGCGGAGGTGGCAGCGGCGGTGGCGGGTCGAG
L2 GCCACCTCCGCCAAGTCCGCCTCCACCGTCGCCGCCACCGCCCAGCTCTTAA
scFv1-Fb GTATGTTGTGTGGAATTGTG
scFv1-R TAGGATCCGTTTGATTTCCACCTTG
scFv2-F TTGAATTCTTGAGGTGCAGCTGTTGGAGTC
scFv2-Rb GTTTTGTCGTCTTTCCAG
a Restriction sites showed by underline.
b Restriction sites of NcoI and NotI are within the PCR products.
Fig. 3. Expression and puriﬁcation of biscFv. A) SDS-PAGE of expression, Coomassie brilliant blue staining. Lane M1 and M2:
PageRuler prestained protein ladder (Thermo ﬁsher scientiﬁc, USA), Lane1: periplasmic extract of E.coli BL21 without pET22-
biscFv plasmids (negative control), Lane2: periplasmic extract before passing into the HisTrap column and lane3: puriﬁed
biscFv. B) Western blot of puriﬁed biscFv using anti-His monoclonal antibody and HRP conjugated goat-anti mouse. Lane M1
and M2: PageRuler prestained protein ladder, lane 1: periplasmic extract of E.coli BL21 without pET22-biscFv plasmid as
negative control, lane 2: periplasmic extract before passing into the HisTrap column, and lane3: puriﬁed biscFv.
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For soluble expression, pET22b-biscFv plasmids, were transformed into E. coli BL21 DE3 (EMD-
Millipore, USA). A single recombinant colony was selected and inoculated overnight in 5 ml 2xTY
containing 100 μg/ml ampicillin at 37 °C. A fresh Terriﬁc Broth (TB) medium containing 100 μg /ml
ampicillin was inoculated with the overnight culture and grown shaken in bafﬂed ﬂasks at 200 rpm at
37 °C until the OD600 reached 0.7–0.8. Then, expression was induced by Isopropylthio-β-galactoside
(IPTG) to a ﬁnal concentration of 0.3 mM, for 4 h at 26 °C. Cells were harvested by centrifugation at
3000 rpm for 30 min, and periplasmic extracts were prepared from pelleted bacteria after a cold
osmotic shock. In brief, bacterial pellets were resuspended in ice-cold 1X TES buffer (0.2 M Tris–HCl
pH 8.0, 0.5 mM EDTA and 0.5 M sucrose). Afterwards, cells were vortexed for 30 s and incubated on
ice for 1 h, followed by resuspension in 2 volumes of TES/4 (1:4 diluted TES with dH2O v/v), incubated
on ice for 3 h. The supernatant containing soluble periplasmic proteins was recovered by
Fig. 4. Competitive binding assays by ELISA and ﬂow cytometry. A. Apparent (Relative) afﬁnity determination of dimeric/
monomeric scFvs formats with the competitive-ELISA method. Antibody afﬁnity was obtained through measuring the IC50.
These results demonstrate that the concentration required for 50% inhibition of the binding was similar for both scFv and
biscFv (red and green dashes, respectively), indicating the same intrinsic afﬁnity.But more biscFv remained bound to immo-
bilized CD123 obtained by ELISA, indicating increase in avidity of biscFv. B) Competitive binding assay of puriﬁed biscFv and
commercial anti-CD123 mAb by ﬂow cytometry. As shown, no obvious shift in ﬂuorescence value were observed with different
concentration of biscFv (added to the cells prior to incubating commercial anti-CD123 mAb compared to background staining
in the absence of biscFv.
Fig. 5. Proliferation -Apoptosis assays by ﬂow cytometry. TF-1 cells were cultured in RPMI with 10% FBS and treated as
describes bellow prior to addition of IL-3 and examined for Annexin V-FITC binding and 7-AAD uptake with ﬂow cytometry
after 24 h treatment. The percentage of cells in the lower right (LR, Annexin Vþ/7-AAD) and upper right (UR, Annexin Vþ/7-
ADDþ) regions, indicate early apoptotic cells and late apoptotic cells respectively. A) Treatment with commercial anti-CD123
mAb. B) Treatment with anti-CD123 biscFv. C) Treatment with anti-CD123 scFv. D) Negative control, Treatment with PBS. E)
Positive control, cells cultured in the absence of IL-3.
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plasmic extract by immobilized metal afﬁnity chromatography (IMAC) using Ni-NTA-Agarose column
(Qiagen, Germany), according to the manufacturer's instructions.
Table 2
Comparison of anti-IL-3 activity of different treatments on TF-1 cells.
Treatments scFv aSD BiscFv SD Commercial Anti-CD123
mAb
SD bControlþ SD cControl SD
dMean % Anti-IL-3
Activity
46.48% 0.64 60.79% 0.70 72.4% 1.1 97.3% 0.87 0.6% 0.37
The results were analyzed with one-way ANOVA and the P valueo0.0001.
a The standard deviation of means from triplicate in given experiment.
b Positive controls (TF-1 cells cultured in the absence of IL-3).
c Negative controls (TF-1 cells treated with PBS).
d Total mean% cells of early and late apoptosis from triplicate in given experiment.
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3.1. SDS-PAGE, Western blotting
Following expression in Ecoli.BL21 and puriﬁcation by immobilized metal afﬁnity chromatography
(IMAC), the Puriﬁed biscFvs were analyzed by SDS-PAGE and western blotting using prestained
Protein Page Ruler (Thermo Fisher Scientiﬁc, USA) as described below. After electrophoresis, the
protein bands were visualized by Coomassie Brilliant Blue staining or were electrophoretically
transferred to a nitrocellulose membrane and blocked for 16 h at 4 °C using 3% BSA in Tris-buffered
saline (TBS), followed by four washes of 5 min in 20 ml of TBS, 0.1% (v/v) Tween 20. Mouse anti-His
tag mAb (Qiagen, Germany) diluted 1:3000 in TBS, was added to detect the biscFv for 1 h at RT.
Following four washes, the membrane was treated with HRP conjugated anti-mouse antibody (Sigma,
Germany), subsequently revealed by 3, 3-diaminobenzidine (DAB) (Sigma, Germany) after four
washes as previously described (Fig. 3).
3.2. Antigen binding activity
Indirect ELISA was performed to evaluate the antigen-binding activity of puriﬁed anti-CD123
biscFv. A microtiter ELISA plate (Maxisorp, Nunc, Denmark) were coated with 100 ml of 1 mg/ml
recombinant CD123 (R&D Systems, USA) in PBS, or PBS alone as a negative control at 4 °C overnight.
After discarding the coating solution, wells were blocked with 3% BSA (w/v) for 1 h at room tem-
perature. Wells were then washed three times with PBST (PBS with 0.05% Tween 20 v/v), followed by
dispersing 100 ml puriﬁed biscFv (1 mg/ml) into the wells for 2 h at room temperature. Then wells
were washed three times with PBST followed by dispersing mouse anti-His tag mAb (1:3000 v/v)
(Qiagen, Germany) into the wells for 1 h at room temperature. Finally the plate was washed, incu-
bated with HRP conjugated anti mouse antibody (Sigma, Germany) for 1 h and the peroxidase activity
was detected by 3, 30, 5, 50-tetramethylbenezidine (TMB) (Sigma, Germany). The reaction was
stopped by 1 M sulfuric acid and color absorbance was determined at 450 nm using an ELISA
microtiter plate reader (Stat Fax 2100, Awarness Technologies, USA).
3.3. Competitive ELISA
To investigate bivalent avidity effects, competitive ELISA were done according to Rath et al. [4].
Brieﬂy, recombinant CD123, was coated in a microtiter ELISA plate at a concentration of 1 μg/ml in
PBS. After washing with PBS and blocking with 3% BSA in PBS, the biscFv and scFv at a concentration
of 1 μg/ml in PBS, were allowed to bind to the immobilized CD123 for 1 h at 37 °C, separately.
Unbound antibodies were removed by three times washing with PBST (PBS with 0.05% Tween 20 v/v).
Recombinant CD123 protein at a decreasing concentrations of 30.3, 15.15, 7.58, 3.79, 1.89, 0.945 nM
were applied to the wells with positive (without antigen) and negative (without biscFv-scFv)controls,
for 1 h at 37 °C. At the end of the incubation time, the plate was washed and bound antibody was
detected as described above. The ratio of antibody molecules remained bound to the plate in the
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was determined and depicted as the concentrations of solution-phase CD123 versus the percentage of
antibody remaining bound to the coated CD123. Subsequently, the binding afﬁnities of scFv and
biscFv for CD123 were determined as IC50 values by GraphPad Prism 5 software (La Jolla, SanDiego,
USA), deﬁned as the concentration of free CD123 that blocked 50% of the antibody binding to the
immobilized CD123 [5,6] (Fig. 4A).
3.4. Competition- binding assay between commercial anti-CD123 mouse mAb and anti-CD123 biscFv by
ﬂow cytometry
To assess whether the binding epitope of our biscFv interferes with binding epitope of commercial
anti-CD123 mAb (BD Pharmingen, USA), a competition-binding assay by ﬂow cytometry was utilized.
5105 TF-1 cells were incubated with the prepared biscFv, with increasing concentration of 5, 10 and
20 mg/ml, for 1 h at 4 °C. Cells were then incubated with a constant concentration of the commercial
anti-CD123 mAb (1 mg/ml) for 1 h at 4 °C. Following, three more washes cells re-incubated with goat
anti-mouse FITC conjugated antibody (1:500 in PBS-FBS 4%) (Abcam, UK) for 1 h at 4 °C. Cells were
then washed and analyzed on a FACS Calibur ﬂow cytometry machine (Partec, Germany). The
obtained data was analyzed using FlowJo 9.7 (Treestar, Ashland, OR) and were shown in Fig. 4B.Acknowledgments
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